Seneviwickrama Maheeka, Gunasekera Kamani M, Gamage Kumindu, Gonapaladeniya Madhusha, Ranasinghe Sriyani
Centre for Cancer Research, University of Sri Jayewardenepura, Nugegoda, Sri Lanka
Department of Community Medicine, Faculty of Medical Sciences, University of Sri Jayewardenepura, Nugegoda, Sri Lanka.
BMJ Open. 2025 Aug 11;15(8):e104450. doi: 10.1136/bmjopen-2025-104450.
Colorectal cancer (CRC) is the third most common cancer and the second leading cause of cancer-related death globally. Growing evidence links gut microbiota dysbiosis to CRC, with several reviews reporting consistent microbial alterations in CRC patients that may serve as non-invasive biomarkers. However, findings vary across studies, and consensus on key microbial taxa is lacking. This umbrella review aims to clarify: (1) the association between gut microbiome composition and CRC development/progression, (2) specific microbial taxa linked to CRC risk, (3) the role of microbiome diversity in CRC outcomes and (4) potential microbial biomarkers for diagnosis, prognosis and treatment response.
This umbrella review will follow the Joanna Briggs Institute (JBI) Umbrella Review Guidelines and adhere to the Preferred Reporting Items for Overviews of Reviews. A comprehensive search will be conducted across MEDLINE (PubMed), Embase, CINAHL and key systematic review databases, including the Cochrane Database, JBI Evidence Synthesis and Database of Abstracts of Reviews of Effects, without language restrictions. The search strategy will use a combination of Medical Subject Headings terms and free-text keywords with Boolean operators. The review questions were developed using the Population, Concept and Context framework. Only high-quality (as determined by the JBI Critical Appraisal Checklist for Systematic Reviews and Research Syntheses), peer-reviewed quantitative systematic reviews with or without meta-analyses will be included. Overall effect estimates extracted from systematic reviews, with the number of studies that inform the outcome, will be presented.
No ethical approval is required since the work is carried out on published documents. Findings of this review will be disseminated among relevant stakeholders through multiple scientific avenues, including presentations at both national and international forums and manuscript publication in an open-access journal.
PROSPERO 2025 CRD420251035257. Available from:https://www.crd.york.ac.uk/PROSPERO/view/CRD420251035257.
结直肠癌（CRC）是全球第三大常见癌症，也是癌症相关死亡的第二大主要原因。越来越多的证据表明肠道微生物群失调与结直肠癌有关，多项综述报告了结直肠癌患者中一致的微生物改变，这些改变可能作为非侵入性生物标志物。然而，不同研究的结果存在差异，对于关键微生物分类群缺乏共识。本伞状综述旨在阐明：（1）肠道微生物群组成与结直肠癌发生/进展之间的关联；（2）与结直肠癌风险相关的特定微生物分类群；（3）微生物群多样性在结直肠癌预后中的作用；（4）用于诊断、预后和治疗反应的潜在微生物生物标志物。
本伞状综述将遵循乔安娜·布里格斯研究所（JBI）伞状综述指南，并遵守综述概述的首选报告项目。将在MEDLINE（PubMed）、Embase、CINAHL和关键系统评价数据库（包括Cochrane数据库、JBI证据综合数据库和效果综述摘要数据库）中进行全面检索，无语言限制。检索策略将结合医学主题词和自由文本关键词以及布尔运算符。综述问题是使用人群、概念和背景框架制定的。仅纳入高质量的（由JBI系统评价和研究综合关键评估清单确定）、经过同行评审的定量系统评价（有无荟萃分析均可）。将呈现从系统评价中提取的总体效应估计值以及为该结果提供信息的研究数量。
由于该工作是对已发表文献进行的，因此无需伦理批准。本综述的结果将通过多种科学途径传播给相关利益攸关方，包括在国内和国际论坛上发表演讲以及在开放获取期刊上发表手稿。
PROSPERO注册号：PROSPERO 2025 CRD42025103,5257。可从以下网址获取：https://www.crd.york.ac.uk/PROSPERO/view/CRD420251035257 。
